United Kingdom (UK)
Recombinant monoclonal antibody to IFNAR-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 64G12.
UniProt Accession Number of Target Protein: P48551
Alternative Name(s) of Target: IFN alpha receptor-1; Interferon alpha/beta receptor 2; IFN-R-2; IFN-alpha binding protein; IFN-alpha/beta receptor 2; Interferon alpha binding protein; Type I interferon receptor 2
Immunogen: The original antibody was generated by immunizing mice with recombinant soluble interferon.
Specificity: The antibody is specific for human IFNAR-1. The epitope to which the antibody binds was found to include the peptide: CNFSSLKLNVYE. This peptide is present in subdomain 1 of the extracellular portion of IFNAR1.
Application Notes: The antibody was able to inhibit the binding of labelled IFN to Daudi cells, K562 cell, HL60 cells and Ly28 cells in a dose-dependent manner. The antibody showed a dose dependent inhibition of the antiviral activity of the various subtypes of type I IFN. Further, in an antiviral assay with the Wish cells, the original antibody was demonstrated to block completely the antiviral activity of Leukocyte IFN, recombinant IFN alpha 2 and interferon from the sera of AIDS patients. The original antibody demonstrated a dose-dependent inhibition of the antiproliferative activity of interferon alpha 2 (US5919453A). The antibody was reported to bind IFNAR-1 with high affinity (KD=1.2x10-9 M). The chimeric and humanized versions of the antibody were constructed (KR1020060011968A).
Antibody first published in: PMID: